Although immunotherapy continues to demonstrate efficacy in a variety of refractory cancers,
currently, no any immunotherapeutic strategy is clinically used for gastric cancer (GC) except …

Increasing evidence indicates that TP53 mutation impacts the patients' prognosis by
regulating the gastric cancer (GC) immunophenotype. An immune prognostic signature (IPS) …

Many studies have shown that TP53 mutations play a negative role in antitumor immunity.
However, a few studies reported that TP53 mutations could promote antitumor immunity. To …

Background. Although immunotherapy has recently achieved clinical successes in a variety
of cancers, thus far there is no immunotherapeutic strategy for breast cancer (BC). Thus, it is …

Remarkable developments in immuno-oncology have changed the landscape of gastric
cancer (GC) treatment. Because immunotherapy intervenes with tumor immune response …

Gastric cancer (GC) is characterized by extreme heterogeneity due to histopathological
differences, molecular characteristics, and immune gene expression signature. Until …

Gastric cancer remains the second most common cause of cancer-related death worldwide.
Because of the poor prognosis of late-stage gastric cancer patients, it is imperative to …

Background: This study aimed to investigate the TP53 mutation, its potential immune
features, its prognostic value, and its impact on immune infiltration in patients with breast …

p53 is a transcription factor that regulates the expression of genes involved in tumor
suppression. p53 mutations mediate tumorigenesis and occur in approximately 50% of …

An intriguing aspect of the tumor suppressor p53 is its ability to communicate to the adaptive
immune system and control the cytotoxic T-lymphocyte (CTL) response to cancer cells. Wild …